header
January 28, 2019

In This Issue
IN THE SPOTLIGHT
MMA's Gordon Smith Named Maine's Director of Opioid Response
AMA Outlines Policy Proposals to Combat Prescription Drug Price Increases
Researchers Say Outpatient Use of Benzodiazepines Increasing
AMA Survey of States: Top Issues Facing Organized Medicine this Year
New Moves by FDA Could Increase Naloxone Access
More Information About the Origins of the Opioid Problem
Medicare-for-all plans: How Do They Compare?
PCSS Offers Free On-line 8-hour X-waiver Course for MAT
129th MAINE LEGISLATURE
MMA Legislative Call Tuesday, January 29th
Report from the State House
UPCOMING EVENTS
Upcoming Specialty Society Meetings
Webinar Presented by Baystate Financial - Sources of Retirement Income
Enrollment Underway for Maine’s Physician Executive Leadership Institute - The Advanced Course - Deadline: January 30, 2019
Identifying Substance Use Early Saves Lives! - SBIRT with Motivational Interviewing Training - 1-day Sessions Offered on Feb 2, Mar 2, Apr 6
HEALTHCARE EMPLOYMENT OPPORTUNITIES
Psychiatric Mental Health NP - Leeds
Urgent Care Physician - South Portland, ME
PCHC in need of Pediatrician at Multiple Locations!
Outpatient Internal Medicine Physician – Bangor, Maine
Full-time Board Certified/Board Eligible MD/DO
Outpatient Family Medicine - Brunswick, Maine
Psychiatric Nurse Practitioner - Nasson Health Care
Opportunities at the VA for Volunteer Physicians
Volunteer Opportunity with Partners for World Health

 
Search Back Issues





 




Follow Us:
New Moves by FDA Could Increase Naloxone Access

One of the most complicated steps in moving a drug from prescription to over-the-counter (OTC) availability is the creation of a medication label that can be easily understood by consumers so that they do not need the advice of a physician about whether, when and how to take the medication. The AMA praised a recent announcement by the Food and Drug Administration (FDA) that it has developed such a label for naloxone—the medication that can prevent opioid overdose deaths by reversing opioid-induced respiratory depression.

This new FDA action is likely to greatly facilitate the development of OTC proposals by manufacturers of the current naloxone products available by prescription. Although many states allow naloxone to be dispensed through a form of prescription known as "standing orders," OTC status would further increase access and save more lives that would otherwise be lost to opioid overdoses.

< Previous Article | Next Article >

[ return to top ]

To ensure delivery of Maine Medicine Weekly Update,
please add 'info@mainemed.com' to your email address book or Safe Sender List.
If you are still having problems receiving our communications,
see our white-listing page for more details: http://www.commpartners.com/website/white-listing.htm


Unsubscribe here

For more information or to contact us directly, please visit www.mainemed.com | ©